Glucagon-like peptide 1 agonists for type 2 diabetes, weight loss, or both?

JAAPA. 2024 May 1;37(5):12-14. doi: 10.1097/01.JAA.0000000000000017. Epub 2024 Apr 25.

Abstract

Glucagon-like peptide 1 agonists (GLP1s) and the novel glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 agonist are effective drugs for reducing A1C and weight in patients with type 2 diabetes. However, clinicians may find it difficult to discern which drug to prescribe in specific clinical scenarios. This article discusses evidence-based clinical use of these drugs.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Exenatide / administration & dosage
  • Exenatide / therapeutic use
  • Gastric Inhibitory Polypeptide / agonists
  • Gastric Inhibitory Polypeptide / therapeutic use
  • Glucagon-Like Peptide 1* / agonists
  • Glucagon-Like Peptide-1 Receptor / agonists
  • Glycated Hemoglobin
  • Humans
  • Hypoglycemic Agents* / therapeutic use
  • Liraglutide / therapeutic use
  • Peptides / therapeutic use
  • Weight Loss* / drug effects

Substances

  • Glucagon-Like Peptide 1
  • Hypoglycemic Agents
  • Liraglutide
  • Gastric Inhibitory Polypeptide
  • Exenatide
  • Peptides
  • Glycated Hemoglobin
  • Glucagon-Like Peptide-1 Receptor